BMO Capital raised the firm’s price target on Merck (MRK) to $135 from $130 and keeps an Outperform rating on the shares after its Q4 earnings beat. The potential Keytruda IP protection, extended through November 2029, could further smooth revenue declines associated with the Keytruda loss of exclusivity, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Merck price target raised to $132 from $124 at BofA
- Merck price target raised to $100 from $95 at Bernstein
- Merck price target raised to $120 from $115 at Citi
- Merck price target raised to $135 from $125 at Wells Fargo
- Hold Steady on Merck: Solid Keytruda Base but Pipeline Uncertainty Keeps Upside Limited